Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Grok 4.1: Features and Improvements xAI says Grok 4.1 makes the chatbot more comfortable to talk to on emotionally heavy topics. The model now picks up nuances and tonalities, allowing it to generate ...

The update marks one of the most significant leaps yet in xAI’s push to create highly capable, emotionally aware, and human-aligned AI systems. Image: Envato “Personality goes a long way,” was a line ...

In what appeared to be a bid to soak up some of Google's limelight prior to the launch of its new Gemini 3 flagship AI model — now recorded as the most powerful LLM in the world by multiple ...

The Zim government has opened its online platform for Form 1 Boarding places application. The Ministry of Primary and Secondary Education made the announcement ...

The Formlabs Form 4 is the latest professional-grade resin 3D printer from the Massachusetts-based manufacturer. Starting at $3,499, it's far above the budget of most hobbyists, and the tested ...

Phase 1 Weapon Banner 5*: Tome of Eternal Flow (Confirmed) and Staff of Homa (Confirmed). 4*: The Dockhand’s Assistant, Portable Power Saw, Favonius Lance, Favonius Codex, and Mitternachts Waltz ...

The IRS on Friday released a draft of Schedule 1-A (Form 1040), Additional Deductions, which includes sections for calculating four deductions allowed under H.R. 1, P.L. 119-21, commonly known as the ...

The military's reserve components now issue departing reservists a new standard service record that summarizes their periods of active and inactive service as well as their "points" earned toward ...

After two years of anticipation, OpenAI has finally launched GPT-5, and it’s full of surprises. Their most advanced AI model yet is now available to all ChatGPT users, even those on the free plan. The ...

In an Aug. 7 earnings call, Eli Lilly CEO David Ricks told investors that the company plans to submit the drug, orforglipron, to the FDA for approval by the end of the year. Dan Skovronsky, chief ...